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Summary.-Hepatitis-B surface antigen (HBSAg) was found in the serum of 58
of 158 (36A4%) southern African Bantu patients with primary hepatocellular cancer
by counter immunoelectrophoresis and in 94 (59 5%o) by radioimmunoassay (RIA).
The prevalence of this antigen in the general Bantu population using these methods
was 7%o and 9%o respectively. Antibody against HB,Ag was detected in 11.6% of
the patients by passive haemagglutination (PH) and 13.4% by RIA, and in 33.4%
(by PH) of a control population. Antibody sub-types were predominantly " adw "
(69-2%) with a lesser frequency of " ayw " (23%), while 7*8% were indeterminate.
The corresponding figures in the controls were 804, 8*4 and 11.2%. HB,Ag was
more common in younger patients. No relationship could be demonstrated between
hepatitis-B antigenaemia and the presence of ox-foetoprotein in high concentration,
although there were far fewer patients in the a-foetoprotein-negative group.
A CAUSAL relationship between chro-
nic hepatitis-B virus (HBV) infection
and primary hepatocellular cancer (PHC)
is suggested by the frequency with which
hepatitis-B surface antigen (HBsAg) (Sher-
lock et al., 1970; Prince et al., 1970;
Vogel et al., 1970; Tong et al., 1971; Kew
et al., 1974) and antibody against hepatitis-
B core antigen (anti-HB,) (Maupas et
al., 1975) are found in the serum of
patients with this tumour. This associa-
tion appears to be particularly strong in
those areas of the world, such as the
Far East and parts of Africa, where
PHC occurs commonly (Prince et al.,
1970; Vogel et al., 1970; Kew et al.,
1974). These areas also appear to have,
in the general population, both a high
carrier rate of HBV (Prince, 1971; Tong
et al., 1971; Hersh et al., 1971; Kew et
al., 1974) and a high incidence of acute
virus-B hepatitis (Tong et al., 1971;
Kew et al., 1974). However, in countries
in which PHC is rare, e.g. the United
States, no obvious relationship between
chronic HBS antigenaemia and the occur-
rence of this tumour has been demon-
strated (Smith and Blumberg, 1970;
Alpert and Isselbacher, 1971; Moertel,
Gleich and Hull, 1970), indicating that
other factors must also be involved in
the aetiology of PHC. Furthermore, the
fact that yet other countries having a
high carrier rate of,the virus and pre-
valence of chronic liver disease associated
with HBV (Theodoropoulos, Archiman-
dritis and Angelopoulos, 1975) have low
or relatively low PHC rates suggests
that the virus may only be oncogenic in
combination with one or more of these
other factors.
In this paper we report the prevalence
of hepatitis-B surface antigen (HBsAg)
and antibody (Anti-HB5) in southern
African Bantu patients with PHC using
the most sensitive laboratory techniques
currently available.
MATERIALS AND METHODS
The study was based on 158 southern
African Bantu patients with PHC. All
but 2 of the patients were males, and theHBSAG AND ANTIBODY IN BANTUS WITH LIVER CANCER
niiajority of these were mine labourers.
Accurate ages were obtained from 87 of
the patients, the mean age for this group
being 39-1 years (range 18-80 years). In 143
patients (90-5%) a histological diagnosis was
made. Although the diagnosis in the re-
mainder was not confirmed histologically,
PHC was strongly suspected because of the
clinical findings, the presence of high con-
centrations of ox-foetoprotein (AFP) in the
serum and the finding of one or more defects
in the liver on hepatic scintiscan.
HBsAg was detected in the serum by
counter immunoelectrophoresis (CIEP)
(Gocke and Howe, 1970) and by solid
phase radioimmunoassay (RIA) using Ausria
11-125 (Ling and Overby, 1970). Specific
antibody against HB,Ag (anti-HBs) was
detected by passive haemagglutination (PH)
(Vyas and Shulman, 1970) and RIA (Gins-
burg et al., 1973). The prevalence ofHBsAg
in the general Bantu as determined by
CIEP was taken from the results of an
earlier investigation (Bersohn et al., 1974).
To determine the prevalence of HB,Ag by
RIA in a control population, serum from
200 apparently healthy Bantu men (100
mine labourers and 100 non-miners) was
examined. The prevalence of anti-HBs in a
coiltrol population was determined by PH
in a group of 431 apparently healthy Bantu,
including 69 mine labourers. AFP was
detected by immunodiffusion (Ouchterlony,
1949) and/or CIEP (Alpert et al., 1971).
In those instances in which the level of the
globulin was too low to be detected by
these nmethods, RIA (Ruoslahti and Seppala,
1971) was used. The normal range for
AFP by RIA was established in 150 healthy
Bantu and 100 healthy White adults.
RESULTS
HB,Ag was found in the serum of 58
of the 158 patients (34.6%) by CIEP
and 94 (59.5%) by RIA. The prevalence
of chronic HBs antigenaemia in the
general rural Bantu population with
these two methods was 700 (Bersohn et
al., 1974) and 9% respectively. All the
positive results with RIA, which were
always confirmed with the neutralizing
antibody technique (Prince et al., 1973),
had ct/min greater than 2 1 times the
mean value established with the negative
TABLE. The Agees ofthe Patients IWith and
WVithout Hepatitis-B. Antigenaemia
Age (years)
Mean
Range
Distribution
<20
20-29
30-39
40-49
50-59
60 and over
<25
>45
HBsAg +Ave
35-5
18-60
2
17 (710%)
17 (68%)
15 (83%)
3 (43%)
3 (27%)
13
10
HBsAg -ve
46 1
24- 80
IIil
7
8
3
4
8
13
13
control sera. All sera positive by CIEP
were also positive by RIA.
The mean age of the patients with
HB,Ag was significantly less (P < 0.001)
than that in those without the antigen
(Table I) and, although the numbers
analysed were small, the antigen ap-
peared to be present more often in
younger patients. In a previous paper
(Kew et al., 1974) we were not able to
show any correlation between hepatitis-B.
antigenaemia and the age of the patients.
One hundred and twelve of the
samples were available for detection of
anti-HB,. Thirteen (11*6%) were positive
by PH (titre range 1/8-1/2040) and 15
(13-4%) by RIA. The prevalence of
anti-HB5 in the controls was 33.40
(titre range 1/8-1/1024). Of the sera
in which anti-HBs was looked for, 44
(39.3%) contained HBSAg by CIEP and
75 (67'%) by RIA. Only two of the
specimens which were positive for anti-
HB, also contained HBsAg, both being
detected only by RIA. Antibody sub-
types (determined by PH) were pre-
dominantly " adw " (69.20o) with a lesser
frequency of " ayw " (23%); 7.8% were
indeterminate. The corresponding figures
in the control population (143) were
80-4, 8-4 and 11-2%.
AFP was detected by immunodiffusion
and/or CIEP in 122 of the 158 patients
(77.2%). Of the 36 samples which were
negative by these methods (i.e. having
a serum concentration of less than 500
ng/ml) 19 gave RIA values above the
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normal range, the concentration varying
from 40-320 ng/ml. The range of AFP
in apparently healthy adults was 1-18
ngiml.
There was no apparent difference in
the prevalence of AFP (by immuno-
diffusion or CIEP) in those with (77.7%)
and without (76.5%) antigenaemia.
HB,Ag was present in 73 (59.8%) of
the patients with AFP and 21 (58.3%)
of those without. It should, however,
be remembered that there were far fewer
patients in the AFP -ve group than in
the AFP +ve group.
DISCUSSION
There is unquestionably an association
between persistent hepatitis-Bs antigen-
aemia and PHC in certain parts of the
world, but its significance has not yet
been established. In southern African
Bantu, in whom the highest prevalences
in the world of this tumour have been
recorded (Doll, Payne and Waterhouse,
1966; Torres, Purchase and van der
Walt, 1970), we have found 60% of the
patients with HBs antigenaemia and
another 12% with measurable levels of
anti-HBs in the serum. A relationship
between chronic HBV infection and PHC
in the Bantu is strengthened by the
finding of antibody against the HBV
core antigen (anti-HB,) in 95% of our
patients (Desmyter, Macnab and Kew,
unpublished data). Even in those pa-
tients without demonstrable antigenaemia,
it is possible that the virus may be
present, either in non-neoplastic liver
cells, or in cirrhotic liver cells (60% of
our patients with PHC have underlying
cirrhosis (Kew et al., 1974)), or even in
the neoplastic hepatocytes. The latter
possibility is supported by our finding
of HB,Ag in the supernatant fluid of
an established PHC cell line in tissue
culture (Macnab and Alexander, un-
published).
The overall prevalence of the HBV
carrier state in the Bantu of southern
Africa is 7% but in some areas it is as
high as 15.8% (Bersohn et al., 1974).
Acute virus-B hepatitis is common in
these people, constituting 54% of cases
of acute viral hepatitis in children and
65% of such cases in adults (Kew et
al., 1974). The prevalence of HBV in
chronic active hepatitis and cirrhosis in
the Bantu has not yet been ascertained.
However, Hadziyannis and Merikas (1973)
have shown that the frequency with
which HBSAg is found in patients with
PHC does not simply reflect a high
incidence of HBsAg +ve cirrhosis in
the same areas. If persistence of HBV
does play a role in the aetiology of PHC,
two possible mechanisms may be con-
sidered. Failure to clear the virus after
an attack of acute hepatitis is known
in some cases to lead to chronic active
hepatitis and cirrhosis (Wright, McCollum
and Klatskin, 1969; Sherlock et at.,
1970), and PHC not infrequently de-
velops in livers which are cirrhotic
(Berman, 1951; MacDonald, 1956; Lin,
1970). HBsAg has been found in associa-
tion with PHC in the absence of cirrhosis
(Kew et al., 1974) so that, alternatively,
the virus may be directly oncogenic.
Although it is tempting to incriminate
HBV in the aetiology of PHC in the
Bantu, the possibility that its frequent
presence is the consequence and not the
cause of the tumour has not definitely
been excluded. No obvious disturbance
in immunological competence could be
found in Ugandan patients with PHC
(Primack, Vogel and Barker, 1973), al-
though a specific defect could not be
excluded. We have not yet investi-
gated the immunological status of our
patients.
It has been suggested that either
AFP is responsible for causing persistence
of HBV (Ziegenfuss, 1973), or that the
virus triggers off AFP synthesis as part
of its oncogenic potential (Alpert and
Isselbacher, 1971). Although our findings
do not appearto support these hypotheses,
the number of samples investigated in
the patients with and without AFP
(detectable by immunodiffusion and/orHBSAG AND ANTIBODY IN BANTUS WITH LIVER CANCER 547
CIEP) were not sufficient to allow definite
conclusions to be drawn.
The evidence that PHC has a multi-
factorial aetiology is convincing. An on-
cogenic role of the virus alone would not
be in keeping with the observation that
in some parts of the world there is no
increase in prevalence of HB,Ag in
patients with this tumour. Nor would
it explain the epidemiological, clinical
and experimental observations which sug-
gest that an androgenic environrment
favours the development ofPHC (Johnson
et al., 1972), or the epidemiological data
incriminating mycotoxins (British Medical
Journal, 1975) or other toxins in the
aetiology ofPHC. However, it is possible
that the virus is oncogenic in combination
with one or more of these factors, and
in the southern African Bantu, chronic
virus-B hepatitis in association with
aflatoxin ingestion may be the cause of
this tumour.
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